Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that predictable routine of Zoom meetings, Skype meetings, and deadlines has returned. Pandemic or no pandemic, the world somehow keeps spinning. So let us embrace the inevitable together with a comforting cup of stimulation and proceed on the journey. Toward that end, here are a few tidbits. Hope your day goes well, and do keep in touch. …

Two Covid-19 vaccine candidates being developed by Pfizer (PFE) and BioNTech (BNTX) received Fast Track designation status from the Food and Drug Administration, Reuters writes. The vaccines are the most advanced of at least four vaccines being assessed by the companies in ongoing trials in the U.S. and Germany. Earlier this month, the companies disclosed that one vaccine, called BNT162b1, showed potential against the virus and was found to be well-tolerated in early-stage human trials. Early data from the German trial of the same vaccine are expected this month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!